A Prospective Cohort of Obinutuzumab and Chlorambucil (GC) Chemotherapy for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia Including Next- Generation Sequencing (NGS)-Based Assessment

Condition:   Chronic Lymphocytic Leukemia Intervention:   Drug: Obinutuzumab Sponsors:   Deok-Hwan Yang;   Roche Pharma AG Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Abstract Chronic lymphocytic leukemia is the most frequent adult leukemia. Eighty per cent of the patients are asymptomatic at diagnosis and 30% of the patients will be never treated. The diagnosis is based on the blood smear examination and immunophenotyping by flow cytometry of blood lymphocytes. The first line option is immunochemotherapy in 90% of the patients without genetic abnormalities associated with chemo resistance. The use of new compounds targeting different pathways is more frequent especially in relapsing patients and could be an alternative to the chemotherapy in the future. Asymptomatic patients w...
Source: Presse Medicale - Category: General Medicine Authors: Tags: Presse Med Source Type: research
Condition:   Chronic Lymphocytic Leukemia Intervention:   Drug: Obinutuzumab Sponsors:   Deok-Hwan Yang;   Roche Pharma AG Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
We report cases of a 39-year-old woman with chronic lymphocytic leukemia and of 21-year-old man with chronic granulomatous disease treated for cerebral aspergillosis. Patients required radical surgery respectively for infection progression despite adequate isavuconazole plasma concentration or neurological complication. We thus decided to measure brain isavuconazole concentration. These results suggest that the concentrations of isavuconazole obtained clearly differ in the infected brain tissue from those obtained in the normal brain tissue and the cerebrospinal fluid. PMID: 31405852 [PubMed - as supplied by publisher]
Source: Antimicrobial Agents and Chemotherapy - Category: Microbiology Authors: Tags: Antimicrob Agents Chemother Source Type: research
AbstractRituximab is the standard of care for most B-cell malignancies. Its rapid clinical development enabled patients to receive this life-prolonging medicine sooner; however, it precluded a thorough assessment of dose selection. Extensive clinical pharmacology data collected from the recent subcutaneous development program enabled re-examination of this old question and support that the approved rituximab dosing regimens in non-Hodgkin ’s lymphoma and chronic lymphocytic leukemia appear to maximize the clinical benefit in the majority of patients.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
Introduction: Chronic lymphocytic leukemia (CLL) is the most frequent form of leukemia in adult population and chemotherapy resistance occurs in 15 –30% of patients with elevated genomic complexity. Apoptosis resistance and induction of a protective form of autophagy are possible explanations of the poor responsivity of CLL to conventional and novel therapeutic drugs. Given the difficulties to maintain in culture B-CLL lymphocytes, the HG3 ce ll line represents an interesting preclinical model to study the effects of natural bioactive molecules or extracts derived from food matrix as potential, chemo-sensitizers in CLL.
Source: Nutrition, Metabolism, and Cardiovascular Diseases : NMCD - Category: Nutrition Authors: Source Type: research
AbstractPurpose of ReviewTreatment of chronic lymphocytic leukemia (CLL) has undergone a major shift since introduction of multiple targeted agents. B cell receptor inhibitors that target either bruton tyrosine kinase (ibrutinib) or phosphatidylinositol 3-kinases (idelalisib and duvelisib) and BCL-2 inhibitor venetoclax have become the mainstay of treatment.Recent FindingsNewer generations of monoclonal antibodies targeting CD20 (obinutuzumab and ofatumumab) are commonly used with novel drugs or chemotherapy agents and result in improved efficacy. At the same time, chemoimmunotherapy remains a reasonable option for selecte...
Source: Current Oncology Reports - Category: Cancer & Oncology Source Type: research
ConclusionThese analyses not only demonstrate that genomic risk factors previously associated with poor outcomes lose their adverse prognostic significance, but also that del(11q) can associate with a superior PFS with ibrutinib therapy.Graphical abstract
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
In this report, we present a case of pembrolizumab-induced autoimmune hemolytic anemia and pancytopenia in a patient who was receiving pembrolizumab treatment for metastatic melanoma. This patient has a history of chronic lymphocytic leukemia and was diagnosed with metastatic melanoma in 2017. He developed symptomatic AIHA and pancytopenia after receiving 8 cycles of pembrolizumab in 2018. Pembrolizumab treatment was discontinued and he was treated with blood transfusion and prednisone. After 5 months of tapering prednisone treatment, his anemia and pancytopenia have improved toward successful recovery. Cancer patients alr...
Source: Case Reports in Oncology - Category: Cancer & Oncology Source Type: research
More News: Chemotherapy | Chronic Leukemia | Chronic Lymphocytic Leukemia | Leukemia | Research